regulusrx.com (RGLS) - Debt to Equity

Regulus Therapeutics leverages the expertise of leading geneticists developing innovative microRNA therapies supported by a generous R&D budget. The business operates within a niche kidney treatment ecosystem where patent success and capital inflows depend on FDA verdicts. The asset's price trajectory, reflecting the 0.03 metric, underscores the non-cyclical nature of biotech and its immunity to inflationary shocks.

This indicator assesses the degree of financial leverage by comparing total liabilities to net assets to determine the business's reliance on borrowed funds. The trend of the total debt-to-equity ratio reflects the balance between external financing and the capital of Regulus Therapeutics (RGLS), which is critical for a biotech startup dependent on partnership grants during the development of RNA drugs.